CDXS

Codexis, Inc. 10-Q Summary: Quarter Ended September 30, 2010

Business Context and Reporting Period

This filing covers the quarterly period ended September 30, 2010. Codexis, Inc. is a developer of proprietary biocatalysts (enzymes and microbes) used to accelerate chemical reactions. The company operates primarily in the pharmaceutical industry and maintains a significant multi-year research and development collaboration with Shell Oil Products US for advanced biofuels. The company completed its Initial Public Offering (IPO) on April 27, 2010.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 35% for the quarter and 32% for the nine-month period compared to the prior year. This was driven by a 105% increase in product revenues (including a $4.5 million sale to Merck) and a 150% increase in non-related party collaborative R&D revenues.
• Profitability: The net loss narrowed significantly to $2.7 million for the quarter from $6.2 million in the prior year quarter. The nine-month net loss decreased to $8.0 million from $15.1 million.
• Liquidity: Cash and cash equivalents increased from $31.8 million at year-end 2009 to $99.3 million at September 30, 2010, primarily due to net proceeds of approximately $67.5 million from the April 2010 IPO.
• Debt: Financing obligations decreased from $7.9 million at year-end 2009 to $4.0 million at September 30, 2010. Note: The company repaid the remaining debt in full in October 2010 (subsequent event).
• Stock-Based Compensation: Expenses increased due to accelerated vesting provisions triggered by the IPO, totaling $6.5 million for the nine months ended September 30, 2010.

Outlook, Risks, and Management Commentary

• Profitability Timeline: Management does not expect to achieve profitability prior to at least 2012 due to continued heavy investment in R&D and administrative infrastructure.
• Customer Concentration: The company remains heavily dependent on Shell, which accounted for 60% of revenues in the quarter and 61% for the nine-month period. The top five customers accounted for 88% of quarterly revenues.
• Key Risks:
  • Collaboration Dependency: Shell has the right to reduce funded Full-Time Equivalents (FTEs) or terminate the agreement, which would materially impact revenues.
  • Internal Controls: The company disclosed a previously identified significant deficiency regarding contract compliance processes. While remediation steps are underway, the company has not yet completed a Section 404 evaluation required for public companies.
  • Manufacturing: Reliance on third-party contract manufacturers (e.g., Arch, CPC, Lactosan) exposes the business to supply chain disruptions.
• Subsequent Events: In October 2010, the company acquired the gene shuffling intellectual property portfolio from Maxygen for $20.0 million and repaid its GE Capital loan in full for $3.7 million.

Investor Verification Checklist

• Shell Agreement Terms: Verify the specific notice periods and FTE reduction rights Shell holds under the collaborative research agreement.
• Product Sales Sustainability: Assess the likelihood of recurring revenue from the $4.5 million Merck sale versus one-time transactional revenue.
• Internal Control Remediation: Monitor progress on remediation of the significant deficiency in contract compliance to ensure future financial reporting accuracy.
• Debt Status: Confirm the October 2010 debt repayment is reflected in subsequent filings and that no new debt obligations have been incurred.
• Maxygen Acquisition: Review the impact of the $20 million IP acquisition on future royalty obligations and R&D expenses.